Quantcast

Latest PDE5 inhibitors Stories

2009-11-18 05:30:00

MOUNTAIN VIEW, Calif., Nov. 18 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from REVIVE (TA-301), a phase 3 pivotal study evaluating the safety and efficacy of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED), in 646 patients. The REVIVE study met all primary endpoints across the three doses studied by demonstrating statistically significant improvement in erectile function as measured by the Sexual Encounter...

2009-11-17 15:01:00

MOUNTAIN VIEW, Calif., Nov. 17 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) plans to announce the results from the avanafil REVIVE (TA-301) phase 3 clinical trial on November 18th prior to market open. The announcement will be followed by a webcast and conference call at 8:30 a.m. Eastern time. Conference Call Information Domestic callers: 1-800-776-0853 International callers: 1-913-312-0980 Webcast information: http://ir.vivus.com. A webcast replay will be available on the...

2009-11-11 06:00:00

MOUNTAIN VIEW, Calif., Nov. 11 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Lazard Capital Markets 6th Annual Healthcare Conference. The VIVUS presentation will take place at The St. Regis in New York, NY on Wednesday, November 18, 2009 at 1:45 p.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com. About VIVUS VIVUS is a...

2009-11-05 06:00:00

MOUNTAIN VIEW, Calif., Nov. 5 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Leland Wilson, chief executive officer, will present an overview of the company at Merriman Curhan Ford's 6th Annual Investor Summit. The VIVUS presentation will take place at the Hotel Sofitel in New York, NY on Tuesday, November 10, 2009 at 8:00 a.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com. About VIVUS VIVUS is a...

2009-11-04 08:00:00

SEOUL, Korea, Nov. 4 /PRNewswire/ -- Dong-A PharmTech Co. Ltd., announced that its U.S. partner, Warner Chilcott plc, has initiated two, phase III trials for udenafil, a new long acting drug under development for erectile dysfunction (ED). Each randomized, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of udenafil, an orally administered selective inhibitor of phosphodiesterase versus placebo. The trials will be conducted in 80 sites in the U.S....

2009-10-20 14:36:08

For patients with erectile dysfunction, treatment with oral medications demonstrates significant improvements in sexual intercourse and erectile function The American College of Physicians (ACP) today issued recommendations for the treatment of erectile dysfunction (ED). ACP, the nation's largest medical specialty organization and second-largest physician group, strongly recommends that physicians initiate therapy with an oral phosphodiesterase type 5 (PDE-5) inhibitor in men who seek...

2009-09-28 07:00:00

MOUNTAIN VIEW, Calif., Sept. 28 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Timothy Morris, chief financial officer, will present an overview of the company at the JMP Securities Healthcare Focus Conference in New York City. The VIVUS presentation will take place at the New York Palace Hotel on Monday, October 5, 2009 at 4:00 p.m. ET. A live...

2009-09-25 07:56:25

Compounds related to Viagra, which is already in clinical trials to prevent heart failure, may also counter the disease in a different way, according to a study published online today in the journal Circulation Research. The results hold promise for the design of a new drug class and for its potential use in combination with Viagra or beta blockers. In heart failure, which affects about 5.7 million Americans, the heart gradually loses the ability to pump with enough force to supply the body...

281d18638b0ccba097f248963c2d625d1
2009-09-21 13:39:25

Scientists reported on Monday that they are in the process of developing a topical anti-impotence cream. Writing in the Journal of Sexual Medicine, scientists from the Albert Einstein College of Medicine at Yeshiva University found that topical versions of Viagra, Levitra and Cialis could be absorbed through the skin with fewer side effects, and quicker reaction time. According to BBC Health, erectile dysfunction pills may have been used by tens of millions of men so far, mostly with great...

2009-09-19 10:17:51

New drug delivery system could significantly lessen side effects An innovative drug-delivery system "“ nanoparticles encapsulating nitric oxide or prescription drugs "“ shows promise for topical treatment of erectile dysfunction (ED), according to a new study by scientists at Albert Einstein College of Medicine of Yeshiva University. The new system, tested successfully on a small number of animals, could potentially prevent side effects associated with oral ED medications, if...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related